Skip to Content

About Us

Therapeutics / Drugs

For more information on UTMDACC technologies, please contact the Office of Technology Commercialization (713-745-9604).  Please indicate the technology number (MDA#) in your correspondence.


MDA10-096
Design and Synthesis of Potent Turmeric Analogues with Enhanced Anti-proliferative, an Anti-tumor Cells Survival Activities as Anti Cancer Agents
Please contact the office for more information on this technology.


MDA10-060
Targeting ALDH1
Please contact the office for more information on this technology.


MDA10-054
Augmenting radiation therapy with nanoparticles
Please contact the office for more information on this technology.


MDA10-050
A Novel Signaling Pathway as a Drug Target for Treatment of Pain Sensitization
http://www.ncbi.nlm.nih.gov/pubmed/21906949


MDA10-049
Platinum-Complex for Molecular Targeted Therapy: Compositions, Manufacturing and Application
Please contact the office for more information on this technology.


MDA10-044
Somatostatin Receptor-Based Therapy
Please contact the office for more information on this technology.


MDA09-084
Method of Treatment of Drug-resistant CML
Please contact the office for more information on this technology.


MDA09-066
Peptidomemetic Inhibitors of STat3
WO2010/118309A2


MDA09-055
Novel Compositions and Methods to Selectively Target Cancer Cells in Stromal Microenvironment and Overcome Drug Resistance
Please contact the office for more information on this technology.


MDA09-050
Tx-262 a Unique Beta Lactam with Unusual Anti-Cancer Activities
Please contact the office for more information on this technology.


MDA09-049
Near-infrared Light Triggered Drug Release from Hollow Gold Nanospheres (HAuNSs) and HAuNSs-Loaded Microspheres
WO2010/014819 A2


MDA09-016
Nanoparticle Formulated Glycolipid Antigens of NKT Cells for Immunotherapy of Cancer and Chronic Viral Diseases
Please contact the office for more information on this technology.


MDA08-154
Combination Therapy with Synthetic Triterpenoids and Gemcitabine
US-2009-0048205-A1
WO/2009/023845


MDA08-138
Novel Nanoparticles Containing a natural compound for Cancer Treatment
WO 2010/065329


MDA07-106
Gleevec Inhibits the Expression of Narcotic Tolerance and Reverses Established Narcotic Tolerance
WO/2009/048947
US2010-0210709


MDA07-102
A Theragnostic Approach to Improve Radiochemotherapy Effects - Method of Use
Please contact the office for more information on this technology.


MDA07-072
Small Molecule Inhibitors for Immune Modulation
WO2008/121858
US 2010-0144802 A1


MDA07-063
Nanoparticles for the Delivery of Therapeutic Agents
WO2009/048958


MDA07-053
Method of Cancer Treatment with Naththol Analogues
WO 2008/106248
US-2010-0152140


MDA07-051
Novel Cannabinoid Compounds
WO2009/012221
WO 2009/012227
US-2010-0204220
US2010-0197755


MDA06-113
Small Molecule Modulators of Signaling Protein Redistribution and Destabilization as Therapeutic Agents
WO2008/005954
US-2010-029229-A1


MDA06-048
Novel e-Kit Inhibitor Based on Protein Wrapping Technology
WO 2008/070350


MDA06-004
Cromolyn as a Cancer Treatment
US-2008-0214491-A1
US-2009-0062319
WO 2010/042504


MDA05-041
A Phase 1-2, Dose Escalation and Efficacy Study of Oral TAC-101 in Patients with Advanced Hepatocelluar Carcinoma
Please contact the office for more information on this technology.


MDA03-038
Antimicrobials in Combination with Chelators and Ethanol for the Rapid Eradication of Microorganisms Embedded in Biofilm
7,601,731
WO2004/108091A2
US-2010-0055086-A1


MDA01-036
Adjuvant Chemotherapy of Anaplastic Gliomas with the Combination of Eflornithine, Lomustine, Matulane, and Vincristine
6,653,351
WO03/015763


MDA99-004
Highly Potent Anthracycline-Based Antitumor Agents
6,437,105
6,680,300
WO00/26223


MDA97-048
Platinum Complexes as Effective Antitumor Agents in Combination with Biochemical Modulation
7,271,161
WO2004/024062


MDA97-046
Chelators in Combination with Biocides: Treatment of Microbially Induced Biofilm and Corrosion
6,267,979
WO/99/10017


MDA96-033
Parenteral Pimaricin as Treatment of Systemic Infections
6,045,815
7,153,838
7,220,726
WO99/08663


MDA96-029
EDTA and Other Chelators With or Without Antifungal Antimicrobial Agents for the Prevention and Treatment of Fungal Infections
6,165,484
6,509,319
US-2003-0032605-A1
WO99/09997


MDA92-022
M-EDTA Pharmaceutical Preparations and Uses Thereof
5,362,754
5,688,516
WO94/10838


MDA90-014
Anthracycline Analogues Bearing Latent Alkylating Substituents
5,196,522
6,284,737
6,433,150
WO92/07866


MDA88-020
Water Soluble 1,2 - Diaminocyclohexane Platinum (IV) Complexes as Antitumor Agents
5,041,578
5,318,962
5,288,887
5,393,909
5,434,256


MDA87-009
Prophylaxis and Therapy of Acquired Immunodeficiency Syndrome
5,128,319
6,210,873
6,265,539
7,319,000
US-2002-0151678-A1
WO91/04045
WO/93/10816

For More Information


© 2014 The University of Texas MD Anderson Cancer Center